NEU neuren pharmaceuticals limited

Acadia, page-1341

  1. 2,540 Posts.
    lightbulb Created with Sketch. 691
    What are people hoping for. I've included my base case where anything above I think would be good, and anything

    1. Q4 revenue ($93m) and CY2024 revenue ($345m) (Midpoint)
    2. CY2025 guidance: North American Daybue Revenue 400bn+ (15%+)

    I think a slightly lower figure for Q4 may be okay provided the guidance/outlook is positive. I think a result of <91m for Q4 paired with a <370m for the full year 2025 could be poorly taken. I think a positive suprise would be >$93m for Q4 and >$400m for 2025 Daybue sales. 400m sales for Daybue is 15% growth in North America which might not seem like much but given Acadia's 1bn+ sales revenue and the analyst expectation of 1.05bn there's no positive expectations baked in at all, given Nuplazid is at a $600bn run rate and even if it grows 5% (630m) that only leaves 370m+ sales of Daybue to get to 1bn+ which is 7.25% YoY growth. Let's hope Acadia are internally looking for 1bn+ but aiming for 1.1m~ revenue for the full year combined Daybue and Nupazlid.
    Last edited by htae39: 26/02/25
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$14.20
Change
0.890(6.69%)
Mkt cap ! $1.761B
Open High Low Value Volume
$13.50 $14.26 $12.96 $9.111M 655.8K

Buyers (Bids)

No. Vol. Price($)
1 2000 $14.17
 

Sellers (Offers)

Price($) Vol. No.
$14.23 3278 1
View Market Depth
Last trade - 16.15pm 27/06/2025 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.